Logo image of SCPH

SCPHARMACEUTICALS INC (SCPH) Stock Fundamental Analysis

USA - NASDAQ:SCPH - US8106481059 - Common Stock

5.67 USD
0 (0%)
Last: 10/6/2025, 9:01:22 PM
5.77 USD
+0.1 (+1.76%)
After Hours: 10/6/2025, 9:01:22 PM
Fundamental Rating

2

SCPH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. SCPH has a bad profitability rating. Also its financial health evaluation is rather negative. SCPH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCPH has reported negative net income.
In the past year SCPH has reported a negative cash flow from operations.
In the past 5 years SCPH always reported negative net income.
In the past 5 years SCPH always reported negative operating cash flow.
SCPH Yearly Net Income VS EBIT VS OCF VS FCFSCPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -114.28%, SCPH is not doing good in the industry: 79.49% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -114.28%
ROE N/A
ROIC N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
SCPH Yearly ROA, ROE, ROICSCPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

SCPH's Gross Margin of 68.46% is fine compared to the rest of the industry. SCPH outperforms 74.87% of its industry peers.
SCPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCPH Yearly Profit, Operating, Gross MarginsSCPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

SCPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCPH has more shares outstanding
Compared to 5 years ago, SCPH has more shares outstanding
SCPH has a worse debt/assets ratio than last year.
SCPH Yearly Shares OutstandingSCPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
SCPH Yearly Total Debt VS Total AssetsSCPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

SCPH has an Altman-Z score of -6.50. This is a bad value and indicates that SCPH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.50, SCPH is doing worse than 63.08% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.5
ROIC/WACCN/A
WACC9.31%
SCPH Yearly LT Debt VS Equity VS FCFSCPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.85 indicates that SCPH has no problem at all paying its short term obligations.
SCPH has a Current ratio of 3.85. This is in the better half of the industry: SCPH outperforms 62.56% of its industry peers.
SCPH has a Quick Ratio of 3.14. This indicates that SCPH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.14, SCPH is in line with its industry, outperforming 59.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.85
Quick Ratio 3.14
SCPH Yearly Current Assets VS Current LiabilitesSCPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SCPH have decreased strongly by -16.03% in the last year.
SCPH shows a strong growth in Revenue. In the last year, the Revenue has grown by 107.75%.
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
Revenue 1Y (TTM)107.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.17%

3.2 Future

The Earnings Per Share is expected to grow by 24.37% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 52.16% on average over the next years. This is a very strong growth
EPS Next Y41.66%
EPS Next 2Y38.35%
EPS Next 3Y33.08%
EPS Next 5Y24.37%
Revenue Next Year100.79%
Revenue Next 2Y88.02%
Revenue Next 3Y72.57%
Revenue Next 5Y52.16%

3.3 Evolution

SCPH Yearly Revenue VS EstimatesSCPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SCPH Yearly EPS VS EstimatesSCPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SCPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCPH Price Earnings VS Forward Price EarningsSCPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCPH Per share dataSCPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as SCPH's earnings are expected to grow with 33.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.35%
EPS Next 3Y33.08%

More info and screens

0

5. Dividend

5.1 Amount

SCPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCPHARMACEUTICALS INC

NASDAQ:SCPH (10/6/2025, 9:01:22 PM)

After market: 5.77 +0.1 (+1.76%)

5.67

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners62.64%
Inst Owner Change-3.58%
Ins Owners5.98%
Ins Owner Change-20.97%
Market Cap304.37M
Revenue(TTM)49.97M
Net Income(TTM)-91716000
Analysts76
Price Target12.33 (117.46%)
Short Float %1.98%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.79%
Min EPS beat(2)-21.73%
Max EPS beat(2)-11.86%
EPS beat(4)1
Avg EPS beat(4)-43.07%
Min EPS beat(4)-147.99%
Max EPS beat(4)9.3%
EPS beat(8)3
Avg EPS beat(8)-18.67%
EPS beat(12)7
Avg EPS beat(12)-7.96%
EPS beat(16)10
Avg EPS beat(16)-3.09%
Revenue beat(2)1
Avg Revenue beat(2)0.56%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)2.03%
Revenue beat(4)1
Avg Revenue beat(4)-2.33%
Min Revenue beat(4)-9%
Max Revenue beat(4)2.03%
Revenue beat(8)4
Avg Revenue beat(8)0.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.49%
EPS NY rev (1m)-1.8%
EPS NY rev (3m)-3.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.09
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.23
OCFYN/A
SpS0.93
BVpS-0.4
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.28%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.46%
FCFM N/A
ROA(3y)-55.62%
ROA(5y)-46.38%
ROE(3y)-279.13%
ROE(5y)-185.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.85
Quick Ratio 3.14
Altman-Z -6.5
F-Score2
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)23.53%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.73%
EPS Next Y41.66%
EPS Next 2Y38.35%
EPS Next 3Y33.08%
EPS Next 5Y24.37%
Revenue 1Y (TTM)107.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%99.17%
Revenue Next Year100.79%
Revenue Next 2Y88.02%
Revenue Next 3Y72.57%
Revenue Next 5Y52.16%
EBIT growth 1Y-10.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.74%
EBIT Next 3Y33.96%
EBIT Next 5YN/A
FCF growth 1Y-29.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.95%
OCF growth 3YN/A
OCF growth 5YN/A

SCPHARMACEUTICALS INC / SCPH FAQ

What is the ChartMill fundamental rating of SCPHARMACEUTICALS INC (SCPH) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SCPH.


What is the valuation status for SCPH stock?

ChartMill assigns a valuation rating of 1 / 10 to SCPHARMACEUTICALS INC (SCPH). This can be considered as Overvalued.


Can you provide the profitability details for SCPHARMACEUTICALS INC?

SCPHARMACEUTICALS INC (SCPH) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SCPHARMACEUTICALS INC?

The Earnings per Share (EPS) of SCPHARMACEUTICALS INC (SCPH) is expected to grow by 41.66% in the next year.